Health and Fitness Health and Fitness
Mon, November 8, 2010
Sun, November 7, 2010
Sat, November 6, 2010
Fri, November 5, 2010
Thu, November 4, 2010
Wed, November 3, 2010
Tue, November 2, 2010
Mon, November 1, 2010
Sat, October 30, 2010
Fri, October 29, 2010
Thu, October 28, 2010
Wed, October 27, 2010
Tue, October 26, 2010
Mon, October 25, 2010
Sun, October 24, 2010
[ Sun, Oct 24th 2010 ] - Market Wire
Alcon Board Elects New Chairman
Sat, October 23, 2010
Fri, October 22, 2010
Thu, October 21, 2010

Teva Invites Public to Listen to Its Respiratory Opportunity Meeting Webcast


//health-fitness.news-articles.net/content/2010/ .. its-respiratory-opportunity-meeting-webcast.html
Published in Health and Fitness on Friday, October 29th 2010 at 10:11 GMT by Market Wire   Print publication without navigation


JERUSALEM--([ BUSINESS WIRE ])--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) will host a live audio webcast of its Respiratory Opportunity Meeting on Thursday, November 4, 2010 at 10:00 a.m. ET.

What:

Tevaa™s Respiratory Opportunity Meeting

Who:

Teva Management

When:

Thursday, November 4, 2010 at 10:00 a.m. ET

Where:

[ www.tevapharm.com/financial/ ] or [ http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=73925&eventID=3437263 ]

How:

Live over the Internet -- log on to the Web at the address above and register for the event (approx. 10 minutes before). An archive of the webcast will be available on Teva's website.

About Teva

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,250 molecules and a direct presence in approximately 60 countries. Teva's branded businesses focus on neurological, respiratory and women's health therapeutic areas as well as biologics. Teva's leading innovative product, Copaxone®, is the number one prescribed treatment for multiple sclerosis. Teva employs more than 40,000 people around the world and reached $13.9 billion in net sales in 2009.


Publication Contributing Sources